Abbott Laboratories $ABT Stock Holdings Lifted by Tsfg LLC

Tsfg LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,253 shares of the healthcare product maker’s stock after buying an additional 3,453 shares during the quarter. Abbott Laboratories accounts for about 2.6% of Tsfg LLC’s portfolio, making the stock its 8th largest position. Tsfg LLC’s holdings in Abbott Laboratories were worth $14,587,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Westside Investment Management Inc. grew its stake in Abbott Laboratories by 10.2% during the 2nd quarter. Westside Investment Management Inc. now owns 2,877 shares of the healthcare product maker’s stock worth $391,000 after buying an additional 267 shares during the last quarter. Texas Bank & Trust Co grew its stake in Abbott Laboratories by 0.7% during the 2nd quarter. Texas Bank & Trust Co now owns 19,323 shares of the healthcare product maker’s stock worth $2,628,000 after buying an additional 127 shares during the last quarter. Hutchens & Kramer Investment Management Group LLC grew its stake in Abbott Laboratories by 16.2% during the 2nd quarter. Hutchens & Kramer Investment Management Group LLC now owns 2,430 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 339 shares during the last quarter. Telos Capital Management Inc. grew its stake in Abbott Laboratories by 0.5% during the 2nd quarter. Telos Capital Management Inc. now owns 30,600 shares of the healthcare product maker’s stock valued at $4,162,000 after purchasing an additional 144 shares during the last quarter. Finally, EPG Wealth Management LLC grew its stake in Abbott Laboratories by 1.4% during the 2nd quarter. EPG Wealth Management LLC now owns 10,606 shares of the healthcare product maker’s stock valued at $1,443,000 after purchasing an additional 151 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $123.61 on Monday. The stock has a market capitalization of $214.94 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 2.36 and a beta of 0.69. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average of $131.45 and a 200 day moving average of $131.61.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.Abbott Laboratories’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Daiwa Capital Markets boosted their price target on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Wells Fargo & Company boosted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Sanford C. Bernstein boosted their price target on Abbott Laboratories from $145.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Finally, Jefferies Financial Group boosted their price target on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.